Bronchogen (Ala-Glu-Asp-Leu) 20mg

What is Bronchogen?

Bronchogen is a synthetic Khavinson-type peptide bioregulator, a four-amino-acid sequence (Ala-Glu-Asp-Leu, AEDL) designed to mirror short regulatory fragments found in bronchial and lung tissue. It belongs to the family of ultra-short peptides developed at the St Petersburg Institute of Bioregulation and Gerontology, where tissue-specific peptides were isolated from organ extracts and later reproduced by chemical synthesis.

Unlike its sibling Chonluten, which was modelled on whole-lung fractions, Bronchogen is associated in the published literature with the bronchial mucosa and the ciliated and secretory cells that line the airways. GenoPept supplies Bronchogen UK-wide as a 20mg lyophilised research peptide for in-vitro study of airway epithelial biology. For background on the whole family, read our guide to Khavinson peptide bioregulators.

Bronchogen research applications

Research on this peptide is confined to preclinical settings, chiefly cell culture and rodent models, with a focus on bronchial and lung epithelium. The areas below summarise where the published literature has investigated the AEDL sequence.

Bronchial epithelial cell culture

Bronchogen has been investigated in organotypic and monolayer cultures of bronchial epithelium, where researchers report changes in proliferation markers and in the expression of proteins associated with epithelial differentiation. These cell-culture models are the main setting in which the AEDL peptide has been characterised.

Airway ageing models

Research explores whether short peptides can influence the functional decline of airway tissue in aged animal models. Bronchogen is studied alongside other bioregulators as a tool for probing age-related changes in mucociliary cells and bronchial gland activity.

Gene-expression profiling

Published work on Khavinson peptides describes altered transcription of signalling and cell-cycle genes after peptide exposure. Bronchogen is used in such profiling experiments to compare tissue-specific responses between lung-derived and non-lung cell lines.

Comparative bioregulator studies

Because the tetrapeptide differs from Chonluten (Glu-Asp-Gly) by only its terminal residues, Bronchogen is a useful comparator in structure-activity work on how residue composition shapes tissue selectivity in ultra-short peptides.

Mechanism of action (preclinical)

The proposed mechanism for Bronchogen follows the general Khavinson model for short peptides. Its small size and mixed charge profile are thought to allow passage across the cell and nuclear membranes, after which the peptide is proposed to interact with DNA in the promoter regions of specific genes and with histone proteins. In bronchial cell cultures this has been linked to increased expression of proliferation markers and of proteins involved in epithelial repair and secretory function. These observations come from in-vitro and animal work; no receptor has been defined for the AEDL sequence and the model remains a hypothesis under investigation.

Bronchogen product specifications

Available sizes

• 20mg vial (lyophilised powder)

This bioregulator is stocked in the UK in a single vial size. Laboratories running larger studies can order bulk boxes of 10 vials at 20–50% off through our bulk and wholesale page.

Reconstitution, handling and storage (laboratory)

Bronchogen is supplied as a lyophilised powder and should be reconstituted only under laboratory conditions. Use bacteriostatic water or a sterile diluent appropriate to your assay. Add the solvent slowly down the inside wall of the vial, swirl gently until the powder dissolves and never shake, as agitation can degrade short peptides. Detailed steps are in our guide to reconstituting research peptides.

Unopened vials should be stored at –20 °C for long-term use, or at 2–8 °C for short periods, protected from light. After reconstitution, keep the solution at 2–8 °C and use it within the period stated in your laboratory protocol. See how to store research peptides for a full summary. Wear gloves and eye protection, work in a clean environment and dispose of residues according to local laboratory rules.

Quality assurance and Certificate of Analysis

Every batch of Bronchogen we supply is tested by Puralytix, an independent ISO/IEC 17025 laboratory, using HPLC to confirm purity of at least 99% and LC-MS to confirm identity against the expected mass of the Ala-Glu-Asp-Leu sequence. The batch Certificate of Analysis is available through the View Certificate of Analysis button on this page and in our COA library. Our explainer on what a Certificate of Analysis shows describes how to read the chromatogram and mass spectrum.

Related research compounds

• Chonluten 20mg – the lung-fraction tripeptide (Glu-Asp-Gly) most often compared with Bronchogen in airway studies
• Vilon 20mg – the thymic dipeptide used as a general immune comparator in bioregulator panels
• Vesugen 20mg – the vascular tripeptide, useful when studying perfusion and endothelial factors in lung models
• Thymosin Alpha-1 (Tα1) Immune Modulator – an immune-signalling peptide often included in respiratory-model research panels

Bronchogen frequently asked questions

What is Bronchogen used for in research?

Bronchogen is used in laboratory research on bronchial epithelial cells and airway tissue ageing. Scientists apply the AEDL tetrapeptide to cell cultures and animal models to study proliferation, epithelial differentiation and gene-expression changes. It is also a standard comparator in structure-activity studies of Khavinson peptides. GenoPept supplies it strictly for in-vitro research use.

How is Bronchogen supplied and what purity should I expect?

GenoPept Bronchogen is supplied as a 20mg lyophilised powder in a sealed, sterile glass vial with a black cap. Every batch is HPLC-tested for purity (at least 99%) and LC-MS confirmed for identity by an independent ISO/IEC 17025 laboratory. The Certificate of Analysis for your lot can be viewed from the product page before you order.

How should Bronchogen be stored in the laboratory?

Store unopened Bronchogen vials at minus 20 degrees Celsius for long-term use, or at 2 to 8 degrees Celsius for short periods, protected from light. After reconstitution keep the solution refrigerated at 2 to 8 degrees Celsius and use it within the timeframe defined in your laboratory protocol. Avoid repeated freeze-thaw cycles.

Is Bronchogen for human use?

No. Bronchogen from GenoPept is for in-vitro laboratory research only. It is not a medicine, not for human or veterinary use and not for diagnostic or therapeutic purposes. No dosing or administration information is provided, and purchasers must be researchers or organisations able to handle research chemicals responsibly under UK regulations.

What is the difference between Bronchogen and Chonluten?

Bronchogen (Ala-Glu-Asp-Leu) is a tetrapeptide associated with bronchial mucosa, whereas Chonluten (Glu-Asp-Gly) is a tripeptide derived from whole-lung fractions. Both are Khavinson bioregulators studied in respiratory models, but they differ in sequence, molecular weight and the cell types most often used to characterise them. Researchers frequently run the two side by side.

Research use only. Bronchogen is sold for in-vitro laboratory research only. It is not for human or veterinary use, not a medicine, and not for diagnostic or therapeutic use. See our research use only policy and UK legal guidance on research peptides.